|
KMID : 0620920230550081672
|
|
Experimental & Molecular Medicine
2023 Volume.55 No. 8 p.1672 ~ p.1677
|
|
|
Reg3γ: current understanding and future therapeutic opportunities in metabolic disease
|
|
Shin Jae-Hoon
Nadejda Bozadjieva-Kramer
Randy J. Seeley
|
|
|
Abstract
|
|
|
|
Regenerating family member gamma, Reg3γ (the mouse homolog of human REG3A), belonging to the antimicrobial peptides (AMPs), functions as a part of the host immune system to maintain spatial segregation between the gut bacteria and the host in the intestine via bactericidal activity. There is emerging evidence that gut manipulations such as bariatric surgery, dietary supplementation or drug treatment to produce metabolic benefits alter the gut microbiome. In addition to changes in a wide range of gut hormones, these gut manipulations also induce the expression of Reg3γ in the intestine. Studies over the past decades have revealed that Reg3γ not only plays a role in the gut lumen but can also contribute to host physiology through interaction with the gut microbiota. Herein, we discuss the current knowledge regarding the biology of Reg3γ, its role in various metabolic functions, and new opportunities for therapeutic strategies to treat metabolic disorders.
|
|
|
KEYWORD
|
|
|
Homeostasis, Type 2 diabetes
|
|
|
FullTexts / Linksout information
|
|
|
|
|
|
Listed journal information
|
|
|
|